Jack Breaks
Analyst, The Fershman Journal. Jack is a first-year at the University of Chicago planning to major in Business Economics and Biology. He is interested in the economics of human health — specifically how shocks in biology (e.g. GLP-1 drugs) rewrite market structure, consumer demand, food systems, and corporate strategy. For Fershman, he is especially interested in writing about the future of obesity drugs, the incentives in the healthcare system, and how investors value treatments that depend on behavior change versus treatments that work at the molecular level.
A $2 Billion Bet on Immunology
Novartis’ $2B Excellergy bet secures its current immunology portfolio while gambling on the future returns of a still-developing drug.
The Globalisation of Digital Health
Hims & Hers’ tabindex="-1".15bn acquisition of Eucalyptus signals a shift from local telehealth startups to global platforms. By controlling the distribution of weight-loss drugs, the company is betting on subscription healthcare at scale.
Pfizer’s $5 Billion GLP-1 Bet Looks Like a Catch-Up Trade
Pfizer’s acquisition of Metsera comes at a steep price: nearly three times the company’s valuation just eight months earlier. After abandoning its own GLP-1 program, Pfizer is paying a large premium to reenter the obesity market late. But the deal raises a question of whether Pfizer already lost?